Physician profile
Anuj Sharma
NPI 1932420957
$2,661.74
in general payments reported to CMS, 2019-2025
29 companies · $199 in 2025
The $199 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $261 · 2020: $186 · 2021: $259 · 2022: $157 · 2023: $934 · 2024: $665 · 2025: $199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,654 · Education: $145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,653.73 |
| Education | $144.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $556.34 | 2021-2025 | Linzess, Skyrizi, Viberzi |
| Janssen Biotech, INC. | $509.62 | 2022-2024 | Stelara |
| Ironwood Pharmaceuticals, INC | $232.37 | 2020-2024 | Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $172.10 | 2020-2023 | Xifaxan |
| Regeneron Healthcare Solutions, INC. | $150.05 | 2022-2025 | Dupixent |
| Redhill Biopharma INC. | $147.07 | 2020-2022 | |
| Pfizer INC. | $123.44 | 2021-2025 | |
| Medtronic Vascular, INC. | $100.00 | 2019 | |
| Allergan, INC. | $97.95 | 2019 | |
| Madrigal Pharmaceuticals | $71.34 | 2024-2025 | Resmetirom, Rezdiffra |
| Takeda Pharmaceuticals U.S.A., INC. | $58.39 | 2019-2023 | Gattex |
| Genzyme Corporation | $45.35 | 2025 | |
| Gilead Sciences, INC. | $44.97 | 2020-2022 | |
| Qol Medical, LLC | $42.51 | 2024 | Sucraid |
| Boston Scientific Corporation | $36.00 | 2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $31.91 | 2021-2022 | |
| Romark Laboratories, Lc | $26.55 | 2019 | |
| Shield Therapeutics INC | $23.76 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.26 | 2024 | Jardiance |
| Aimmune Therapeutics, INC. | $21.49 | 2025 | Zenpep |
| Alnylam Pharmaceuticals INC. | $21.29 | 2024 | Givlaari |
| Celgene Corporation | $19.47 | 2021 | |
| Medtronic, INC. | $17.93 | 2021 | |
| Intercept Pharmaceuticals, INC. | $17.54 | 2022 | |
| Phathom Pharmaceuticals, INC. | $15.79 | 2024 | Voquezna |
| Mallinckrodt Hospital Products INC. | $15.65 | 2024 | Terlivaz |
| Echosens North America, INC. | $15.15 | 2024 | Fibroscan |
| Covidien LP | $12.74 | 2019 | |
| Capsovision, INC. | $12.71 | 2023 | Capsocam Plus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anuj Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.